Electrophysiological Characteristics of a SCN5A Voltage Sensors Mutation R1629Q Associated With Brugada Syndrome

Zhipeng Zeng, Jieqiong Zhou, Yuxi Hou, Xiaojing Liang, Ziguan Zhang, Xuejing Xu, Qiang Xie, Weihua Li*, Zhengrong Huang*

Department of Cardiology, the First Affiliated Hospital of Xiamen University, Xiamen, China

Abstract

Brugada syndrome (BrS) is an inherited arrhythmogenic syndrome leading to sudden cardiac death, partially associated with autosomal dominant mutations in SCN5A, which encodes the cardiac sodium channel alpha-subunit (Na\textsubscript{v}1.5). To date some SCN5A mutations related with BrS have been identified in voltage sensor of Na\textsubscript{v}1.5. Here, we describe a dominant missense mutation (R1629Q) localized in the fourth segment of domain IV region (DIV-S4) in a Chinese Han family. The mutation was identified by direct sequencing of SCN5A from the proband’s DNA. Co-expression of Wild-type (WT) or R1629Q Na\textsubscript{v}1.5 channel and hβ1 subunit were achieved in human embryonic kidney cells by transient transfection. Sodium currents were recorded using whole cell patch-clamp protocols. No significant changes between WT and R1629Q currents were observed in current density or steady-state activation. However, hyperpolarized shift of steady–state inactivation curve was identified in cells expressing R1629Q channel (WT: \(V_{1/2} = -81.1 \pm 1.3\) mV, \(n = 13\); R1629Q: \(V_{1/2} = -101.7 \pm 1.2\) mV, \(n = 18\)). Moreover, R1629Q channel showed enhanced intermediate inactivation and prolonged recovery time from inactivation. In summary, this study reveals that R1629Q mutation causes a distinct loss-of-function of the channel due to alter its electrophysiological characteristics, and facilitates our understanding of biophysical mechanisms of BrS.

Citation: Zeng Z, Zhou J, Hou Y, Liang X, Zhang Z, et al. (2013) Electrophysiological Characteristics of a SCN5A Voltage Sensors Mutation R1629Q Associated With Brugada Syndrome. PLoS ONE 8(10): e78382. doi:10.1371/journal.pone.0078382

Editor: Zhe Zhang, Xuzhou Medical College, China

Received July 9, 2013; Accepted September 14, 2013; Published October 22, 2013

Copyright: © 2013 Zeng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by Chinese National Science Foundation (No. 81170090 and No 81270277). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

* E-mail: huangzhengrong1@gmail.com (ZH); liweihuaxm@hotmail.com (WL)

Introduction

Brugada syndrome (BrS) is a heritable arrhythmia syndrome characterized by an ST segment elevation in ECG leads V\textsubscript{1} to V\textsubscript{3} and an increased risk for sudden cardiac death (SCD) due to ventricular fibrillation (VF) [1]. BrS is estimated to account for 4% of all SCD and 20% of unexplained sudden deaths without obvious structural heart disease [2]. To date, more than ten different genes have been associated with BrS [3,4]. The major disease gene for BrS is SCN5A, a gene encoding the primary alpha-subunit of the cardiac sodium channel (Na\textsubscript{v}1.5), accounting for 10-30% of subjects with BrS carrying a SCN5A gene mutation with autosomal dominant inheritance [2,5]. Recently, over 300 SCN5A mutations have been identified in BrS patients [6-8]. The BrS mutant channels which have been characterized so far in vitro revealed loss-of-function by a variety of mechanisms, including reduced current density or represented abnormal biophysical characteristics [7-10]. However, despite many studies, the molecular and cellular mechanisms underlying BrS are still not completely known.

Voltage-gated sodium channels play a key role in initiation and propagation of cardiac action potential that is essential for the rhythm beating of the heart. Moreover, mutations in SCN5A and auxiliary subunits genes (SCN1B-4B) have been found to be associated with a various inherited arrhythmia syndromes that includes BrS, long QT syndrome type 3 (LQT3), progressive cardiac conduction defect (PCCD), sick sinus node syndrome, atrial fibrillation and even dilated cardiomyopathy (DCM) [10]. The identification of SCN5A mutation in patients with inherited arrhythmogenic syndromes is critical for the understanding of the pathogenesis of arrhythmias. It could provide practical information that is very helpful for optimal patient management and risk stratification [11,12]. In addition, understanding the structural-functional relationship of the Na\textsubscript{v}1.5 will shed new light on exploiting new therapeutic drugs for SCN5A channelopathies.
In this study, we described a Chinese Han family with two male patients diagnosed of BrS, one of which died of SCD. Screening of the SCN5A gene from the proband resulted in the detection of a heterozygous mutation R1629Q in the voltage sensor of domain IV. To understand the molecular mechanisms determining the malignant phenotype, we analyzed biophysical properties of mutant sodium channel in HEK293 cells.

**Methods**

**Ethics Statement**

This study was approved by the Medical Ethical Committee of the first affiliated hospital of Xiamen University (Xiamen, China) and conformed with the principles outlined in the Declaration of Helsinki. Blood samples were obtained after written informed consent.

**Clinical Data**

A family composed of 9 subjects that belong to the Chinese Han population (six males, three females, mean age 47.2 ± 25.5 years) underwent physical examination, basal biochemical marker detection, resting 12-lead ECG, 24h Holter ECG, echocardiogram, and genetic screening for the SCN5A mutation. The family was studied after the investigation of the proband (55-year-old man) was admitted to the hospital due to the onset of a sustained polymorphic ventricular tachycardia (254 bpm) recorded at the arrival to the emergency room (B): Twelve-lead ECG recording of the proband with Brugada syndrome at baseline, showing prominent coved ST-segment elevation, following a negative T wave in V1-V2 leads, and ST-segment saddleback elevation in V3 lead (Type I BrS ECG).

**Figure 1. Twelve-lead ECG recording of the proband with Brugada syndrome.** (A): ECG monitor strip of the proband showing polymorphic ventricular tachycardia (254 bpm) recorded at the arrival to the emergency room (B): Twelve-lead ECG recording of the proband with Brugada syndrome at baseline, showing prominent coved ST-segment elevation, following a negative T wave in V1-V2 leads, and ST-segment saddleback elevation in V3 lead (Type I BrS ECG).

doi: 10.1371/journal.pone.0078382.g001

**Mutation Analysis of SCN5A in BrS**

Genomic DNA was extracted from blood sample using Puregene DNA purification Kit (Tiangen biotech, Beijing, China). Previously published primer pairs were used to amplify all exons and exon-intron boundaries of SCN5A gene from genomic DNA [13]. Polymerase chain reaction (PCR) products were purified (Tiangen biotech, Beijing, China) and they were directly sequenced for mutation using ABI Prism 3730XL DNA sequencer (Applied Biosystems, Foster City, CA, USA). The DNA sequence and amino acid were based on the SCN5A transcript NM_198056.2 [14]. DNA samples from 150 healthy Chinese Han individuals (300 alleles) were used as control samples.

**Mutagenesis and Heterologous Expression**

Wild-type (WT) human heart SCN5A cDNA (Uniprot reference: Q14524-1) and Na1.5 channel hβ1-subunit SCN1B cDNA (Uniprot reference: Q07699-1) subcloned into pcDNA3 and pIRE2-DsRed vector for mammalian expression, respectively. Both the plasmids, generous gifts from Dr. Qing K. Wang, were described previously [15,16]. R1629Q mutation was created by site-directed mutagenesis using overlap extension PCR on the basis of pcDNA3-hH1 template and the following primers (mutation underlined):

5′-GGCTATTCTGGGGCCAGGGGATGAC-3′and 5′-CGCCTGGCCCAATAGGGGCGATCCT-3′.
The mutant clone was confirmed by direct sequencing. For patch-clamp studies, HEK293 cells, a kind gift from Dr. Qing K. Wang, were cultured as previous methods [16]. Cells were transiently cotransfected with 0.8 µg pcDNA3-

SCN5A (WT or mutants) and 0.8 µg of pIRES2-DsReD-SCN1B as a reporter gene using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), following the manufacturer’s instructions. All experiments were performed 48 hours after transfection.

**Cellular Electrophysiology**

Sodium currents were recorded at room temperature (22°C-25°C) using whole cell patch-clamp technique as previous methods [16]. The experiments were conducted with an MultiClamp™ 700B amplifier and pClamp 10.1/Digidata 1440A acquisition system (Molecular Devices, Sunnyvale, CA, USA). The data was analyzed by OriginPro8 software (OriginLab Corporation, Northampton, MA, USA). The curves of activation and steady-state inactivation were fitted to a Boltzmann function (Equation 1) where $y$ is the normalized current or conductance, $V_m$ is the membrane potential, $V_{1/2}$ is the voltage at which half of the channels are activated or inactivated and $k$ is the slope factor [7,16,17]. Recovery curves from inactivation were fitted with two-exponential equation (Equation 2), in which values for $A$ and $\tau$ refer to amplitudes and time constants, respectively [16,17]. Decay characteristic of the fast transient current was fitted to a single-exponential equation over a range of voltages from -50 mV to -30 mV, from where time course were obtained [17].

**Statistical Analysis**

Statistical data were reported as means ± standard error (SE) unless otherwise noted. Statistical comparisons between wild-type and mutation groups were tested using the unpaired Student’s t-test. $P < 0.05$ was considered statistically significant.

**Results**

**Clinical Evaluation**

The proband (I1, Figure 2A), a 56-year-old man, was admitted to hospital because of PVT (Figure 1A) terminated with electrical cardioversion. At rest, electrocardiogram showed sinus rhythm and a prominent coved ST-segment elevation >2mm, following a negative T wave in V1-V2 leads, in accordance with BrS type I ECG (Figure 1B). The proband’s son (II1) showed Type I pattern characterized by ST-segment elevation in right precordial leads and had a history of unexplained syncope occurring at rest. Despite carrying R1629Q mutation, individual II3 was asymptomatic and just showed suspicious Type II ECG pattern. In addition, the remaining family members had normal baseline ECG, X-ray and 2D-echocardiogram, screening no mutation in SCN5A gene. The proband refused the therapy of the implantable cardioverter defibrillator due to financial condition. During the follow-up (22 months) the patient died of SCD.

**Molecular genetics**

Mutation screening was performed on genomic DNA in the exons and exon-intron boundaries coding sequences of SCN5A gene by direct sequencing. A single heterozygous nucleotide transition (G to A) at position 4886 of the SCN5A gene (c.4886 G>A) was identified in proband’s DNA. This base
transition results in arginine replaced by glutamine at position 1629 (p.R1629Q) of the Na$_v$1.5 channel in the affected cases (Figure 2B). Interestingly, the R1629Q mutation localizes on the fourth trans-membrane segment of domain IV (DIV-S4), regarded as voltage sensor of sodium channels. R1629 is highly conserved within in Na$_v$1.5 channel of other mammal species by sequence alignment (Figure 2C). Absence of SCN5A c.4886A allele in 150 control individuals (300 chromosomes), Human Gene Mutation Data base (HGMD) [18], Ensembl [19] and HapMap [20] suggested that it was a possible mutation causing BrS rather than a rare polymorphism. The mutation was also confirmed in the proband’s two sons (II1; II3).

Results of the Cellular Electrophysiological Study

We subsequently compared the biophysical properties of wild-type recombinant human Na$_v$1.5 channels (WT) or R1629Q channels in the presence of hβ1 subunit in HEK293 cells at room temperature (22°C-25°C). To control membrane size, sodium currents were recorded in the whole-cell patch clamp configuration and current amplitudes were divided by the membrane area calculated from the electrode tip size. Both WT and R1629Q channels give rise to typical inward currents that completely deactivate within milliseconds (Figure 3A). In fact, we observed no significant difference in current density between WT and R1629Q (Table 1). Therefore, the R1629Q mutation is probable not a gross structural mutation disrupting channel trafficking and/or the stability of the channel.

Despite no change between WT and R1629Q channel is observed in current density, the R1629Q mutation represents abnormal kinetic properties of Na$_v$1.5 channel (Table 1). Accordingly, R1629Q has no significant effect on the channel activation, as can be seen from the voltage dependence activation (Table 1, Figure 4A). However, Na$_v$1.5 R1629Q displays a 20.6 mV negative shift of the steady-state inactivation curve toward more negative potentials (WT: $V_{1/2} = -81.1 \pm 1.3$ mV, $n=13$; R1629Q: $V_{1/2} = -101.7 \pm 1.2$ mV, $n=18$; $P<0.01$), and a faster onset of inactivation measured as time course of current decay compared with WT Na$_v$1.5 (Table 1, Figure 3), that reveals that Na$_v$1.5 R1629Q induces a significant preferential transition into the deactivation. We compared the differences in the kinetics of recovery from inactivation induced by a 500-ms depolarization to -20 mV, followed by a variable recovery interval at -120 mV for WT or R1629Q channel. The recovery curve for both channels is most in keeping with two exponential components where the fast time constant $\tau_f$ and the slow time constant $\tau_s$ are acquired. $\tau_f$ in R1629Q channel is significantly slower as compared to WT channel (Table 1, Figure 4B).

In addition, we also examined whether R1629Q channel exhibits an alteration in intermediate inactivation which might be a particular biophysical mechanism of BrS. Intermediate

---

**Figure 3. R1629Q mutation affects the time course of current decay.** (A) Example current traces of WT (open circle) and R1629Q (filled square) channels. (B) A shows typical normalized current traces recorded in response to -40mV step for WT (solid line) and R1629Q (dash line) SCN5A channels. The decay of $I_{Na}$ was fit to a mono-exponential ($\tau$ time constants) decay function. Note that the decay of the R1629Q channels was faster than WT. (C) Current decay time constants for WT (open circle) and R1629Q (filled square) between -50mV and 30mV. *$P<0.05$ vs. WT in this study. Results are expressed as means±SE for 6 to 11 cells.

doi: 10.1371/journal.pone.0078382.g003
inactivation process, defined as a form of inactivation occurring over a time period of a few hundred milliseconds to tens of seconds, has an important physiological implications in determining the channels availability for firing action potential [21]. Some studies described that certain SCN5A mutations (T1620M, 1795insD et al) associated with BrS functionally reduced cardiac sodium current in the myocardium by enhancing the entry process of the channel into an intermediate inactivated state [21,22]. To find whether R1629Q mutation affects the process, we recorded the time dependence of the intermediate inactivation state for the WT or R1629Q channel. With the prolongation of the pulse duration, sodium currents decreased much more notably in cells expressing R1629Q than in those transfected with WT. Differences between WT and R1629Q were significant at all prepulse durations at the level of \( P<0.05 \).

After a 1000-ms depolarization to -20 mV then a 10-ms repolarizing step to -120 mV to allow recovery from fast inactivation, the proportional decrement in channel availability was 3.6-fold greater for R1629Q than WT (WT 19.6±1.5%, R1629Q 75.8±0.1%).

Table 1. The Kinetic Parameters for WT and R1629Q channels.

|                     | Activation | Inactivation | Decay(-40mV) | Recovery from inactivation |
|---------------------|------------|--------------|--------------|---------------------------|
|                     | \( pA/pF \) | \( n \)     | \( V_{1/2}(mV) \) | \( k \) | \( n \) | \( \tau \) (ms) | \( t_{f}(ms) \) | \( t_{s}(ms) \) | \( n \) |
| WT                  | 30         | 34.5±1.5     | 0.6±0.3      | 8 | -81.1±1.3 | 5.2±0.1 | 13 | 2.3±0.2 | 6 | 3.2±0.2 | 6 | 104.1±20.0 | 11 |
| R1629Q              | 22         | 32.2±1.4     | 6.4±0.2      | 11 | -101.7±1.2** | 5.8±0.1* | 18 | 1.18±0.1* | 11 | 22.5±1.0** | 139.0±14.0 | 12 |

Each entry is the mean ± SE obtained from \( n \) experiments. For the Boltzmann fit (activation and inactivation) the parameters are: \( V_{1/2} \) midpoint and slope factor (\( k \)). For the double-exponential fit (recovery) the parameters are: \( \tau_{f} \) the fast time constant; \( \tau_{s} \) the slow time constant; for the single exponential fit (decay) the parameter is: \( \tau \) the time constant. All parameters were analyzed by t-test. * \( P<0.05 \) vs WT, ** \( P<0.01 \) vs WT.

doi: 10.1371/journal.pone.0078382.t001

Figure 4. R1629Q alters \( Na_{v1.5} \) channel inactivation kinetics and prolongs the recovery time from inactivation. (A) Voltage dependence of steady-state activation and inactivation curve of WT (open circle) and R1629Q (filled square) channels. The protocol was shown in the Inset and Values for the half-maximal voltage (\( V_{1/2} \)) were provided in the table 1. (B) Time courses of recovery from inactivation were investigated using the two-pulse protocol show in the inset. Time constants are as follows: WT, \( \tau_{f}=3.2±0.2\text{ms}, \tau_{s}=104.1±20.0\text{ms}, n=11; \) R1629Q, \( \tau_{f}=22.5±1.0\text{ms}, \tau_{s}=139.0±14.0\text{ms}, n=12. \) (Comparison of \( \tau_{f} \) between groups is statistically significant. \( P<0.01 \)). Results are presented as mean±SE.

doi: 10.1371/journal.pone.0078382.g004
n=9; versus R1629Q 69.6±1.4%, n=8, P<0.01 (Figure 5A), indicated the R1629Q mutant showed a significant preferential transition into the intermediate inactivation state than WT. As shown in Figure 5B, to elucidate the potential pathophysiological significance of this effect, we recorded peak sodium currents during a series of 300–ms test depolarization to -20 mV from holding potential -120 mV. Currents are normalized to the value obtained after the first pulse and plotted against the successive pulse number. The residual normalized current level recorded after 30th pulse is 39.4%±2.1% for WT (open circles, n=14) and 18.7%±2.1% for R1629Q (filled squares, n=15) (P<0.01). Therefore, our results exhibit that the mutation R1629Q causes Na\textsubscript{v}\textsubscript{1.5 channels enhanced accumulation of I\textsubscript{Na} into an intermediate inactivated state. To sum up, R1629Q mutation may alter the electrophysiological properties of Na\textsubscript{v}1.5 channels, causing the loss-of-function of sodium channels.

**Discussion**

In this study, we identified a SCN5A mutation (R1629Q) associated with a severe clinical cardiac disorder BrS in a Chinese Han family. Although the R1629Q mutation was recently identified in a sporadic BrS patient, convincing pathophysiological mechanism attributed to BrS has still not been investigated [6]. The R1629Q mutation localizes in a highly conserved position which consists of an arginine to glutamine substitution for the third basic residue in DIV-S4, counting from the extracellular (amino) end of S4. Currently, there are some mutations associated with SCN5A channelopathies localized in this voltage sensor domain [6,10]. We analyze biophysical properties of mutated R1629Q Na\textsubscript{v}1.5 channel in vitro. Our data reveals that the mutation R1629Q induces an evident loss-of-function of cardiac sodium channel by shifting voltage dependence of inactivation, enhanced intermediate inactivation as well as prolonged recovery time from inactivation.

In the family, the two affected individuals (I1 and II1) were heterozygous carriers of the c.4886A allele. The mutation carrier (II3) has not been diagnosed as BrS due to merely showing saddleback (Type II) ECG pattern. However, there were several findings that supported the pathogenic nature of this heterozygous mutation: a) only individuals heterozygous for the missense mutation showed some characteristics of BrS; b) SCN5A c.4886G>A was not screened in samples from a large control group and some DNA databases, therefore eliminating a single nucleotide polymorphism; c) the R1629 residue in the voltage sensor segment 4 of domain IV was
SCN5A Mutation R1629Q Associated With BrS

The heterozygous mutation carrier II3 showed normal cardiac function without syncope and cardiac arrhythmia, and rejected to perform ajmaline challenge test. Due to the variability of ECG pattern in BrS patients and no performing pharmacological test in the II3 individual, the man cannot rule out the diagnosis of BrS [27].

Abnormalities of right ventricular for outflow wall motion and contraction have been detected in some patients with BrS [28-30]. However, to date most people still consider BrS is non-organic and heterogeneous heart rhythm disorder. The most attractive and well-convincing hypothesis to explain the basic electrophysiological mechanism of BrS involves loss-of-function of cardiac sodium channel, resulting in the imbalance of inward and outward current especially by the existence of a transmural repolarization gradient in the right ventricular wall where disproportionate expression of the transient outward current [21,31]. More than 300 SCN5A mutations are identified in BrS [6-8]. Most of them are missense mutations (193 mutations, account for 66%), and tend to cluster around the trans-membrane spanning region [6].These studies revealed that SCN5A mutations linked to BrS resulted in the loss-of-function of the Na\textsubscript{1.5} channels in heterologously expressed systems [7-10].Various distinct mechanisms are known to produce loss-of-function, including reduced expression of the channel in the plasma membrane to decrease sodium current, shifted curves of the voltage dependence of the channel activation or inactivation, or changed the characteristics of channel kinetic [10].

In the presence of the hβ1 subunit, the current density of the R1629Q channel is similar to WT. However, the mutation R1629Q leads to a distinct loss-of-function of Na\textsubscript{1.5} channels by distinct abnormal biophysical characteristics, such as hyperpolarizing shift of inactivation: prolonging fast recovery time from inactivation, and increasing entrance into the intermediate inactivation. These results suggest the mutation R1629Q does not affect channel expression and its ability to generate inward current in HEK293 cells, possibly because the mutation does not grossly disrupt the cardiac sodium channel folding, trafficking or function. But, the abnormality in electrophysiological properties caused by R1629Q mutation significantly disturbs the sodium channel activity responsible for increased transmural of dispersion repolarization, and might subsequently lead to phase 2 reentrant extrasystoles, and predispose the patient to VT and VF [21,31].

Interestingly, many evidences revealed that the S4 segment was postulated to function as voltage sensors in voltage-gate channels. However, DI-III are primarily involved in activation, whereas DIV has a distinct role in inactivation by applying specific toxins [32], site-directed fluorescence labeling [33] and paddle chimeras methods [23]. Many studies suggested that mutations in the DIV voltage sensors may affect slow and fast inactivation of Na\textsubscript{1.5} and other Na\textsubscript{v} channels, exhibiting a possible tight coupling between the DIV voltage sensors and inactivation [23-26,32].Recently, Chanda and coworkers [34] showed that activation of the DIV voltage sensor might induced a conformational change of the pore necessary for fast inactivation to occur. However, it remains unclear whether DIV voltage sensors involve in intermediate inactivation which plays an important role in determine the channels availability during firing action potential. Our findings further suggest that the S4 segments in DIV may affect intermediate inactivation gating process and its stability of sodium channels. Moreover, there are a growing number of reports that mutations associated with SCN5A channelopathies resided in the voltage-sensor domain [10].For example, SCN5A mutations preferentially inclined to occur in the S4 segment in DCM patients, and among positive charge clusters acted as voltage sensor [35,36]. These mutations resulted in the functional defects of sodium channels with synthesis of a channel protein altered gating kinetics rather than reduced the current density [10,37]. Since the DIV-S4 plays a critical role in the inactivation of sodium channels, it was hardly surprising that R1629Q mutation altered the availability and intermediate inactivation of Na\textsubscript{1.5} channels.

In conclusion, we identified a heterozygous human mutation (R1629Q) in the voltage sensor of DIV-S4, causing malignant phenotype of a lethal arrhythmia secondary to VT/VF in a Chinese Han family. Although the mutation, R1629Q, has no significant effects on current density or steady-state activation, it can disrupts the electrophysiological characteristics of Na\textsubscript{1.5} channel by hyperpolarizing shift in steady–state activation, decreasing the decay time course, preferentially enhancing intermediate inactivation and prolonging recovery time from inactivation. Our findings may facilitate the understanding of arrhythmogenesis mechanisms of BrS and the role of DIV-S4 in Na\textsubscript{1.5} channels.

Acknowledgements

The authors acknowledge the study subjects for their participation in and support of this project. Without their support, this study would not have been possible. The authors thank Yuan Huang and Qing K. Wang, College of Life Science and Technology and Center for Human Genome Research, Huazhong University of Science and Technology, Wuhan, China, for their outstanding support and kindly providing plasmid.

Author Contributions

Conceived and designed the experiments: ZRH WHL. Performed the experiments: ZPZ JOZ YXH XJL ZGZ XJX. Analyzed the data: ZPZ WHL QX ZRH. Wrote the manuscript: ZPZ ZRH.
References

1. Chen PS, Priori SG (2008) The Brugada syndrome. J Am Coll Cardiol 51: 1176-1180. doi:10.1016/j.jacc.2007.12.006. PubMed: 18355655.
2. Antzelevitch C, Brugada P, Borggreve M, Brugada J, Brugada R et al. (2005) Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 111: 659-670. doi:10.1161/01.CIR.0000152479.54298.51. PubMed: 15655131.
3. Berne P, Brugada J (2012) Brugada syndrome 2012. Circ J 76: 1563-1571. doi:10.1253/circj.CJ-12-0717. PubMed: 22789973.
4. Ishikawa T, Takahashi N, Ohno S, Sakurada H, Nakamura K et al. (2013) Novel SCN3B mutation associated with brugada syndrome affects intracellular trafficking and function of Nav1.5. Circ J 77: 959-967. doi:10.1253/circj.CJ-12-0995. PubMed: 23257389.
5. Bai R, Napolitano C, Bloise R, Monteforte N, Priori SG (2009) Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. Circ Arrhythm. J Electrophysiol 2: 6-15.
6. Kapplinger JD, Tester DJ, Alders M, Benito B, Berthet M et al. (2010) An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm 7: 33-46. doi:10.1016/j.hrthm.2009.09.069. PubMed: 20129263.
7. Tarradas A, Selga E, Beltran-Alvarez P, Perez-Serra A, Rirou H et al. (2013) A novel missense mutation, I890T, in the pore region of cardiac sodium channel causes Brugada syndrome. PLOS ONE 8: e53220. doi:10.1371/journal.pone.0053220. PubMed: 23308164.
8. Calloe K, Refaat MM, Grubb S, Wojcik J, Campagna J et al. (2013) Characterization and mechanisms of action of novel Nav1.5 channel mutations associated with Brugada syndrome. Circ Arrhythm. J Electrophysiol 6: 177-184.
9. Antzelevitch C, Noé E (2008) Brugada syndrome: recent advances and controversies. Curr Cardiol Rep 10: 376–383. doi:10.1007/s11886-008-0060-y. PubMed: 18175534.
10. Zimmer T, Surber R (2008) NCSCA channelopathies—an update on mutations and mechanisms. Prog Biophol Mol Biol 98: 120-136. doi: 10.1016/j.pbiomolbio.2008.10.005. PubMed: 19027780.
11. Ackerman MJ, Priori SG, Willemis S, Benul C, Brugada R et al. (2011) HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 8: 1308-1339. doi:10.1016/j.hrthm.2011.05.020. PubMed: 21787999.
12. Schwartz PJ, Ackerman MJ, George AL Jr, Wilde AA (2013) Impact of Genetics on the Clinical Management of Channelopathies. J Am Coll Cardiol 62: 169-180. doi:10.1016/j.jacc.2013.04.044. PubMed: 23364863.
13. Wang Q, Shen J, Splawski I, Atkinson D, Li Z et al. (1995) SCNSA mutations associated with inherited cardiac arrhythmia, long QT syndrome. Cell 80: 805-811. doi:10.1016/0092-8674(95)90359-3. PubMed: 115.6.707. PubMed: 10828245.
14. Capes DL, Goldschen-Ohm MP, Arcisio-Miranda M, Bezanilla F, Chanda B (2013) Domain IV voltage-sensor movement is both sufficient and rate limiting for fast inactivation in sodium channels. J Gen Physiol 142: 101-112. doi:10.1085/jgp.201309996. PubMed: 23858005.
15. Veltmann C, Schirmpf R, Echternach C, Eckardt L, Kuschky J et al. (2006) A prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome: Implications for correct phenotyping and risk stratification. Eur Heart J 27: 2544-2552. doi:10.1016/j.eurheartj.2005.06.050. PubMed: 16952022.
16. Takagi M, Alihara N, Kuriyayashi S, Taguchi A, Kurita T et al. (2003) Abnormal response to sodium channel blockers in patients with Brugada syndrome: augmented localised wall motion abnormalities in the right ventricular outflow tract region detected by electron beam computed tomography. Heart 89: 169-174. doi:10.1136/heart.89.2.169. PubMed: 12526760.
17. Tukkie R, Sogaard P, Vleugels J, de Groot IK, Wilde AA et al. (2004) Delay in right ventricular activation contributes to Brugada syndrome. Circulation 109: 1272-1277. doi:10.1161/01.CIR.0000118467.53182.D1. PubMed: 14993143.
18. Huang ZR, Chen LL, Li WH, Tang OZ, Huang CX et al. (2007) Interventricular septum motion abnormalities: unexpected echocardiographic changes of Brugada syndrome. Chin Med J (Engl) 120: 1898-1901. PubMed: 18067765.
19. Yan GX, Antzelevitch C (1999) Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 100: 1660-1666. doi:10.1161/01.CIR.100.15.1660. PubMed: 10517739.
20. Sheets MF, Kyle JW, Kallen RG, Hanck DA (1999) The Na channel voltage sensor associated with inactivation is localized to the external charged residues of domain IV, S4. Biophys J 77: 747-757.
21. Chanda B, Bezanilla F (2002) Tracking voltage-dependent conformational changes in skeletal muscle sodium channel during activation. J Gen Physiol 120: 629-645. doi:10.1085/jgp.20026879. PubMed: 12407076.
22. Goldschen-Ohm MP, Capes DL, Oelstrom KM, Chanda B (2013) Multiple pore conformations driven by asynchronous movements of voltage sensors in a eukaryotic sodium channel. Nat Commun 4: 1350. doi:10.1038/ncomms2356. PubMed: 23322038.
23. McNair WP, Sinagra G, Taylor MR, Di Lenarda A, Ferguson DA et al. (2011) SCN5A mutations associated with arrhythmogenic dilated cardiomyopathy and commonly localize to the voltage-sensing mechanism. J Am Coll Cardiol 57: 2160-2168. doi:10.1016/j.jacc.2010.09.084. PubMed: 21596231.
24. Mann SA, Castro ML, Ohanian M, Guo G, Zodkekar P et al. (2012) R222Q SCN5A mutation is associated with reversible ventricular ectopy and dilated cardiomyopathy. J Am Coll Cardiol 60: 1566-1573. doi:10.1016/j.jacc.2012.05.050. PubMed: 22999724.
25. Nair K, Pekhlentski R, Harris L, Care M, Morel C et al. (2012) Escape capture bigeminy: Phenotypic marker of cardiac sodium channel voltage sensor mutation R222Q. Heart Rhythm. 9: 1681-1688. doi:10.1016/j.hrthm.2012.06.029. PubMed: 22710484.